Treatment of Patients With Recurrent High-Grade Glioma With APG-157 and Bevacizumab
Clinical trial NCT06011109 · RECRUITING
Trial details
- NCT number
- NCT06011109
- Sponsor
- Aveta Biomics, Inc.
- Status
- RECRUITING
- Phase
- Phase 1, Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2023-12-13
- Primary completion
- 2026-12-31
- Enrollment
- 30
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.